The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Dual targeting strategies with bispecific antibodies
Open accessAbstract
Monoclonal antibodies are widely used for the treatment of cancer, inflammatory and infectious diseases and other disorders. Most of the marketed antibodies are monospecific and therefore capable of interacting and interfering with a single target. However, complex diseases are often multifactorial in nature, and involve redundant or synergistic action of disease mediators or upregulation of different receptors, including crosstalk between their signaling networks. Consequently, blockade of multiple, different pathological factors and pathways may result in improved therapeutic efficacy. This result can be achieved by combining different drugs, or use of the dual targeting strategies applying bispecific antibodies that have emerged as an alternative to combination therapy. This review discusses the various dual targeting strategies for which bispecific antibodies have been developed and provides an overview of the established bispecific antibody formats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Malam, Y., Loizidou, M., & Seifalian, A. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.004 · Cited by 1,318
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
Th17 Cell Differentiation: The Long and Winding Road
McGeachy, M. J., & Cua, D. J. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.001 · Cited by 701
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Self-citationFcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications
Smith, K. G. C., & Clatworthy, M. R. (2010) · Nature Reviews Immunology · doi:10.1038/nri2762 · Cited by 543
Passive antibody therapy for infectious diseases
Casadevall, A., Dadachova, E., & Pirofski, L.-A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro974 · Cited by 531
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
Ashkenazi, A., Holland, P., & Eckhardt, S. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7198 · Cited by 421
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Bostrom, J., Yu, S.-F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 370
Immunotoxin Treatment of Cancer
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.070605.115320 · Cited by 359
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
Weinblatt, M., Schiff, M., Goldman, A., Kremer, J., Luggen, M., Li, T., Chen, D., & Becker, J.-C. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055111 · Cited by 300
pH-Sensitive liposomes-principle and application in cancer therapy
Karanth, H., & Murthy, R. S. R. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.4.0001 · Cited by 294
Seimetz, D., Lindhofer, H., & Bokemeyer, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.001 · Cited by 284
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects
Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117382 · Cited by 280
Platelet-derived Growth Factor Signaling and Human Cancer
Yu, J.-H., Ustach, C., & ChoiKim, H.-R. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.049 · Cited by 269
Fenske, D. B., & Cullis, P. R. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.25 · Cited by 253
Molecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 246
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Kontermann, R. E. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00003 · Cited by 243
Self-citationFuture directions of liposome- and immunoliposome-based cancer therapeutics
Park, J. W., Benz, C. C., & Martin, F. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.009 · Cited by 240
Antibody-based therapeutics to watch in 2011
Reichert, J. M. (2011) · mAbs · doi:10.4161/mabs.3.1.13895 · Cited by 236
Design and production of novel tetravalent bispecific antibodies
Coloma, M. J., & Morrison, S. L. (1997) · Nature Biotechnology · doi:10.1038/nbt0297-159 · Cited by 236
Tao, Y., Pinzi, V., Bourhis, J., & Deutsch, E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0934 · Cited by 230
A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers
Saul, J. M., Annapragada, A. V., & Bellamkonda, R. V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.028 · Cited by 227
Pedersen, M. W., Jacobsen, H. J., Koefoed, K., Hey, A., Pyke, C., Haurum, J. S., & Kragh, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1417 · Cited by 219
Tugues, S., Koch, S., Gualandi, L., Li, X., & Claesson-Welsh, L. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.004 · Cited by 205
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.-W., Matys, E. R., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202
Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.001 · Cited by 198
Davis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., & Huston, J. S. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzp094 · Cited by 194
Veeken, J., Oliveira, S., Schiffelers, R., Storm, G., Henegouwen, P. M. P., & Roovers, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789271495 · Cited by 189
Lu, D., Zhang, H., Koo, H., Tonra, J., Balderes, P., Prewett, M., Corcoran, E., Mangalampalli, V., Bassi, R., Anselma, D., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500815200 · Cited by 180
Monoclonal antibody-based therapies for microbial diseases
Saylor, C., Dadachova, E., & Casadevall, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.105 · Cited by 172
Antibody-modified liposomes for cancer chemotherapy
Torchilin, V. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.9.1003 · Cited by 168
Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics
R BOARD, & Jayson, G. C. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.03.004 · Cited by 149
Kluza, E., van der Schaft, D. W. J., Hautvast, P. A. I., Mulder, W. J. M., Mayo, K. H., Griffioen, A. W., Strijkers, G. J., & Nicolay, K. (2009) · Nano Letters · doi:10.1021/nl902659g · Cited by 144
Goldenberg, D. M., Rossi, E. A., Sharkey, R. M., McBride, W. J., & Chang, C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046185 · Cited by 143
Kügler, M., Stein, C., Kellner, C., Mentz, K., Saul, D., Schwenkert, M., Schubert, I. A., Singer, H., Oduncu, F. S., Stockmeyer, B., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08300.x · Cited by 137
Bispecific Antibodies for Cancer Immunotherapy: Current Perspectives
Müller, D., & Kontermann, R. E. (2010) · BioDrugs · doi:10.2165/11530960-000000000-00000 · Cited by 137
Self-citationCandida and invasive candidiasis: back to basics
Lim, C. S. Y., Rosli, R., Seow, H. F., & Chong, P. P. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1273-3 · Cited by 130
Growth factor receptor interplay and resistance in cancer
Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D., & Nicholson, R. I. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01275 · Cited by 130
Wozniak‐Knopp, G., Bartl, S., Bauer, A., Mostageer, M., Woisetschläger, M., Antes, B., Ettl, K., Kainer, M. A., Weberhofer, G., Wiederkum, S., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq005 · Cited by 126
A bispecific nanobody to provide full protection against lethal scorpion envenoming
Hmila, I., Saerens, D., Abderrazek, R. B., Vincke, C., Abidi, N., Benlasfar, Z., Govaert, J., Ayeb, M. E., Bouhaouala‐Zahar, B., & Muyldermans, S. (2010) · The FASEB Journal · doi:10.1096/fj.09-148213 · Cited by 125
Chemical generation of bispecific antibodies
Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., van Hagen, C., Levin, N. J., Shields, M. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016478108 · Cited by 124
Lu, D., Zhang, H., Ludwig, D. L., Persaud, A., Jimenez, X., Burtrum, D. B., Balderes, P. J., Liu, M., Böhlen, P., Witte, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310132200 · Cited by 124
Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity
Laginha, K. M., Mumbengegwi, D. R., & Allen, T. M. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.02.007 · Cited by 119
Yang, W., Klos, K. S., Yang, Y., Smith, T. L., Shi, D., & Yu, D. (2002) · Cancer · doi:10.1002/cncr.10553 · Cited by 118
Michaelson, J. S., Demarest, S. J., Miller, B., Amatucci, A., Snyder, W. B., Wu, X., Huang, F., Phan, S., Gao, S. X., Doern, A., et al. (2009) · mAbs · doi:10.4161/mabs.1.2.7631 · Cited by 116
Ludovini, V., Bellezza, G., Pistola, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn727 · Cited by 116
Bernardis, F. D., Liu, H., O’Mahony, R., Valle, R. L., Bartollino, S., Sandini, S., Grant, S., Brewis, N., Tomlinson, I. M., Basset, R. C., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509891 · Cited by 114
Rudman, S. M., Jameson, M. B., McKeage, M. J., Savage, P. M., Jodrell, D. I., Harries, M., Acton, G. D., Erlandsson, F., & Spicer, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2490 · Cited by 109
Moore, G. L., Bautista, C., Pong, E., Nguyen, D.-H. T., Jacinto, J. M., Eivazi, A., Muchhal, U. S., Karki, S., Chu, S. Y., & Lazar, G. A. (2011) · mAbs · doi:10.4161/mabs.3.6.18123 · Cited by 104
Onda, M., Beers, R., Xiang, L., Lee, B., Weldon, J. E., Kreitman, R. J., & Pastan, I. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102746108 · Cited by 103
A modular IgG-scFv bispecific antibody topology
Orcutt, K. D., Ackerman, M. E., Cieslewicz, M., Quiroz, E., Slusarczyk, A. L., Frangioni, J. V., & Wittrup, K. D. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp077 · Cited by 102
Vallera, D. A., Todhunter, D. A., Kuroki, D. W., Shu, Y., Sicheneder, A., & Chen, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2290 · Cited by 99
Resistance to epidermal growth factor receptor-targeted therapy
Morgillo, F., & Lee, H. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.08.004 · Cited by 95
Wu, C., Hua, Y., Bose, S., Miller, R., Medina, L., Santora, L. C., & Ghayur, T. (2009) · mAbs · doi:10.4161/mabs.1.4.8755 · Cited by 94
Rader, C. M., Sinha, S. C., Popkov, M., Lerner, R. A., & Barbas, C. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931308100 · Cited by 93
Immunoliposomes for cancer therapy.
Kontermann, R. E. (2006) · PubMed · Cited by 91
Self-citationKoefoed, K., Steinaa, L., Søderberg, J. N., Kjær, I., Jacobsen, H. J., Meijer, P., Haurum, J. S., Jensen, A. D., Kragh, M., Andersen, P. S., et al. (2011) · mAbs · doi:10.4161/mabs.3.6.17955 · Cited by 91
Jackman, J. K., Chen, Y., Huang, A. J. Y., Moffat, B., Scheer, J. M., Leong, S. R., Lee, W. P., Zhang, J., Sharma, N., Lu, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113910 · Cited by 91
Therapeutic potential of anticancer immunotoxins
Choudhary, S., Mathew, M., & Verma, R. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.04.003 · Cited by 90
Nellis, D. F., Ekstrom, D. L., Kirpotin, D. B., Zhu, J., Andersson, R., Broadt, T. L., Ouellette, T. F., Perkins, S. C., Roach, J. M., Drummond, D. C., et al. (2005) · Biotechnology Progress · doi:10.1021/bp049840y · Cited by 88
Vallera, D. A., Chen, H., Sicheneder, A. R., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.02.006 · Cited by 87
Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller, D., & Kontermann, R. E. (2007) · PubMed · Cited by 82
Self-citationTam, S. W., Demissie, S., Thomas, D., & Daëron, M. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00332.x · Cited by 81
Dong, J., Sereno, A., Aivazian, D., Langley, E. J., Miller, B., Snyder, W. B., Chan, E., Cantele, M., Morena, R., Joseph, I. B. J., et al. (2011) · mAbs · doi:10.4161/mabs.3.3.15188 · Cited by 80
Kellner, C., Bruenke, J., Stieglmaier, J., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318186c8b4 · Cited by 78
Emanuel, S. L., Engle, L. J., Chao, G., Zhu, R.-R., Cao, C., Lin, Z., Yamniuk, A. P., Hosbach, J., Brown, J. M., Fitzpatrick, E., et al. (2011) · mAbs · doi:10.4161/mabs.3.1.14168 · Cited by 74
Verı́, M.-C., Burke, S., Huang, L., Li, H., Gorlatov, S. N., Tuaillon, N., Rainey, G. J., Ciccarone, V. C., Zhāng, T., Shah, K., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27477 · Cited by 74
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., & Chang, C. (2009) · Blood · doi:10.1182/blood-2008-10-187138 · Cited by 72
B cell depletion therapy in rheumatic disease
Edwards, J., Cambridge, G., & Leandro, M. J. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.05.010 · Cited by 68
Dong, J., Demarest, S. J., Sereno, A., Tamraz, S., Langley, E. J., Doern, A., Snipas, T., Perron, K., Joseph, I. B. J., Glaser, S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1018 · Cited by 68
Augmentation of antitumor effects of p53 Gene therapy by combination with HDAC inhibitor
Takimoto, R., Kato, J., Terui, T., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.4.1620 · Cited by 67
Engineering and characterization of a bispecific HER2 × EGFR‐binding affibody molecule
Friedman, M., Lindström, S., Ekerljung, L., Svahn, H. A., Carlsson, J., Brismar, H., Gedda, L., Frejd, F. Y., & Ståhl, S. (2009) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090096 · Cited by 67
Jimenez, X., Lu, D., Brennan, L., Persaud, K., Liu, M., Miao, H., Witte, L., & Zhu, Z. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0261 · Cited by 66
Le, X., Mao, W., Lu, C., Thornton, A., Heymach, J. V., Sood, A. K., & Bast, R. C. (2008) · Cell Cycle · doi:10.4161/cc.7.23.7212 · Cited by 65
Todhunter, D. A., Hall, W. A., Rustamzadeh, E., Shu, Y., Doumbia, S., & Vallera, D. A. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh023 · Cited by 65
Lu, D., Jimenez, X., Witte, L., & Zhu, Z. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.060 · Cited by 63
Schanzer, J., Jekle, A., Nezu, J., Lochner, A., Croasdale, R., Dioszegi, M., Zhang, J., Hoffmann, E., Dormeyer, W., Stracke, J. O., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00215-10 · Cited by 62
Inhibition of allergen-specific IgE reactivity by a human Ig Fcγ-Fcε bifunctional fusion protein
Zhang, K., Kepley, C. L., Terada, T., Zhu, D., Pérez, H., & Saxon, A. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.03.058 · Cited by 61
Management of asthma with anti-immunoglobulin E: A review of clinical trials of omalizumab
Nowak, D. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2005.10.004 · Cited by 59
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
Mabry, R., Lewis, K. E., Moore, M. D., McKernan, P. A., Bukowski, T. R., Bontadelli, K., Brender, T., Okada, S. L., Lum, K. D., West, J. W., et al. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp073 · Cited by 59
Schubert, I. A., Kellner, C., Stein, C., Kügler, M., Schwenkert, M., Saul, D., Mentz, K., Singer, H., Stockmeyer, B., Hillen, W., et al. (2011) · mAbs · doi:10.4161/mabs.3.1.14057 · Cited by 58
DARPins as Bispecific Receptor Antagonists Analyzed for Immunoglobulin E Receptor Blockage
Eggel, A., Baumann, M. J., Amstutz, P., Stadler, B. M., & Vogel, M. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.08.014 · Cited by 58
Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes
Meng, S., Su, B., Li, W., Ding, Y., Tang, L., Zhou, W., Song, Y., Li, H., & Zhou, C. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/41/415103 · Cited by 58
Qu, Z., Goldenberg, D. M., Cardillo, T. M., Shi, V., Hansen, H. J., & Chang, C. (2007) · Blood · doi:10.1182/blood-2007-08-110072 · Cited by 57
Ueda, S., Hatsuse, K., Tsuda, H., Ogata, S., Kawarabayashi, N., Takigawa, T., Einama, T., Morita, D., Fukatsu, K., Sugiura, Y., et al. (2006) · Modern Pathology · doi:10.1038/modpathol.3800582 · Cited by 57
Kontermann, R. E. (2010) · PubMed · Cited by 56
Self-citationMabry, R., Gilbertson, D. G., Frank, A., Vu, T., Ardourel, D., Ostrander, C. D., Stevens, B. L., Julien, S. H., Franke, S., Meengs, B., et al. (2010) · mAbs · doi:10.4161/mabs.2.1.10498 · Cited by 56
Antibody–cytokine fusion proteins: applications in cancer therapy
Ortíz-Sánchez, E., Helguera, G. F., Daniels‐Wells, T. R., & Penichet, M. L. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.5.609 · Cited by 56
A novel DDS strategy, “dual-targeting”, and its application for antineovascular therapy
Murase, Y., Asai, T., Katanasaka, Y., Sugiyama, T., Shimizu, K., Maeda, N., & Oku, N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.008 · Cited by 55
Single Variable Domain-IgG Fusion
Shen, J., Vil, M. D., Jimenez, X., Iacolina, M. D., Zhang, H., & Zhu, Z. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513415200 · Cited by 49
Koning, G. A., Morselt, H. W. M., Gorter, A., et al. (2003) · Pharmaceutical Research · doi:10.1023/a:1025009300562 · Cited by 48
Laventie, B., Rademaker, H. J., Saleh, M., de Boer, E., Janssens, R., Bourcier, T., Subilia, A., Marcellin, L., van Haperen, R., Lebbink, J. H. G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102265108 · Cited by 48
The IL-12/IL-23 axis and its role in Th17 cell development, pathology and plasticity in arthritis.
Cornelissen, F., van Hamburg, J. P., & Lubberts, E. (2009) · PubMed · Cited by 48
Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme
Hall, W. A., & Vallera, D. A. (2006) · Neurosurgical FOCUS · doi:10.3171/foc.2006.20.4.15 · Cited by 46
Rossi, E. A., Rossi, D. L., Stein, R., Goldenberg, D. M., & Chang, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2126 · Cited by 46
Stish, B. J., Chen, H., Shu, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2454 · Cited by 45
Hammoudi-Triki, D., Lefort, J., Rougeot, C., Robbe-Vincent, A., Bon, C., Laraba‐Djebari, F., & Choumet, V. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.11.003 · Cited by 43
Di-diabody: a novel tetravalent bispecific antibody molecule by design
Lu, D., Jimenez, X., Zhang, H., Atkins, A., Brennan, L., Balderes, P. J., Böhlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00251-5 · Cited by 42
Shen, J., Vil, M. D., Zhang, H., Tonra, J. R., Rong, L., Damoci, C., Prewett, M. C., Deevi, D. S., Kearney, J. A., Surguladze, D., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.075 · Cited by 40
Skartved, N. J. Ø., Jacobsen, H. J., Pedersen, M. W., Jensen, P. F., Sen, J. W., Jørgensen, T. K., Hey, A., & Kragh, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1209 · Cited by 40
Dong, J., Sereno, A., Snyder, W. B., Miller, B., Tamraz, S., Doern, A., Favis, M., Wu, X., Tran, H., Langley, E. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.184317 · Cited by 39
Oh, S., Stish, B. J., Sachdev, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0696 · Cited by 39
Gupta, P., Goldenberg, D. M., Rossi, E. A., & Chang, C. (2010) · Blood · doi:10.1182/blood-2010-03-276857 · Cited by 38
Stish, B. J., Oh, S., & Vallera, D. A. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9499-8 · Cited by 36
Tsai, A. K., Oh, S., Chen, H., Shu, Y., Ohlfest, J. R., & Vallera, D. A. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0392-5 · Cited by 35
Vallera, D. A., Oh, S., Chen, H., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0203 · Cited by 35
Stish, B. J., Oh, S., Chen, H., Dudek, A. Z., Kratzke, R. A., & Vallera, D. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605297 · Cited by 33
Markman, M. M. (2011) · Cancer Management and Research · doi:10.2147/cmar.s15558 · Cited by 31
Emerging antibody combinations in oncology
Demarest, S. J., Hariharan, K., & Dong, J. (2011) · mAbs · doi:10.4161/mabs.3.4.16615 · Cited by 30
Rustamzadeh, E., Vallera, D. A., Todhunter, D. A., Low, W. C., Panoskaltsis‐Mortari, A., & Hall, W. A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9051-7 · Cited by 30
Oh, S., Ohlfest, J. R., Todhunter, D. A., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9932-2 · Cited by 29
Emerging therapies for severe asthma
Thomson, N. C., Chaudhuri, R., & Spears, M. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-102 · Cited by 27
Schoonjans, R., Willems, A. V., Schoonooghe, S., Leœn, J., Grooten, J., & Mertens, N. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00066-1 · Cited by 25
Retargeting T cells and immune effector cells with bispecific antibodies
Lum, L. G., & Davol, P. A. (2005) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(04)22013-0 · Cited by 25
Kontermann, R. E. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9 · Cited by 24
Self-citationTuscano, J. M., Ma, Y., Martin, S. M., Kato, J., & OʼDonnell, R. T. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0978-6 · Cited by 16
Duke‐Cohan, J. S., Morimoto, C., & Schlossman, S. F. (1993) · Blood · doi:10.1182/blood.v82.7.2224.2224 · Cited by 11
Recombinant proteins in rheumatology – recent advances
Rothe, A., & RUBBERT, A. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.019 · Cited by 3
Cited by
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Self-citationOvercoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Metadata
- Authors
- Kontermann, R.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2012-03
- Volume
- 4
- Issue
- 2
- Pages
- 182-197
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2033439473
- Cited by
- 435
- References
- 135
- FWCI
- 30.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.